New Blood Test Detects Pancreatic Cancer Earlier—A Game-Changer?
Pancreatic cancer is one of the most devastating diagnoses a person can receive. It lurks in the body, undetected, until it’s too late.
There are no obvious warning signs, no reliable early screening tools, and by the time symptoms appear—pain, jaundice, digestive issues—the disease has already spread.
That’s why pancreatic cancer has one of the worst survival rates of any major cancer.
In fact, 75% of patients die within the first year of diagnosis.
For years, doctors have been desperate for a reliable way to catch this cancer early. And now, a new blood test may finally offer some hope.
Until now, the only FDA-approved biomarker for pancreatic cancer has been CA 19-9, a test that is shockingly unreliable in early-stage disease. Its sensitivity for catching pancreatic cancer in stage I is just 31%—meaning nearly 70 % of cases are missed when the cancer is most treatable.
But scientists at Oregon Health & Science University have developed a revolutionary new test called PAC-MANN-1 that detects pancreatic cancer with far greater accuracy.
Here’s what makes it different:
It detects cancer’s hidden signals. PAC-MANN-1 works by identifying protease activity—enzymes that break down proteins and are significantly elevated in pancreatic cancer.
It’s a simple blood test. Unlike complex imaging scans or invasive biopsies, this test requires just a small blood sample and a simple fluorescent readout—making it cheaper and more accessible.
Plus, it’s far more sensitive than current methods. When combined with CA 19-9, the detection rate for stage I pancreatic cancer jumps to 85%—a major breakthrough.
The cruel truth about pancreatic cancer is that early diagnosis can mean the difference between life and death.
If caught in stage I, surgery can be curative. But by stage IV, survival drops to just 3%.
That’s why PAC-MANN-1 is such a game-changer. By detecting cancer earlier than ever before, it could give patients a fighting chance before the disease becomes unstoppable.
But there’s a catch…
While the PAC-MANN-1 test is highly promising, it’s not yet available to the public. And like all medical breakthroughs, Big Pharma will likely swoop in to monetize it—potentially making it expensive and out of reach for those who need it most.
The test also isn’t perfect yet. It still requires lab processing, meaning it’s not available in pharmacies or for at-home use. Researchers hope to refine it into a point-of-care test that could be more widely accessible.
Pancreatic cancer has remained one of the deadliest diseases because we haven’t had a way to detect it early—until now.
The PAC-MANN-1 test is a huge step forward, potentially saving countless lives by catching this silent killer before it’s too late.
But will Big Pharma make it accessible? Or will it be another life-saving breakthrough reserved for those who can afford it?
For now, the science is clear: early detection is possible. Here at e-Alert we’ll continue to keep you updated as more information becomes available.
To beating cancer before it beats us,
Rachel Mace
Managing Editorial Director, e-Alert
with contributions from the research team
Sources:
Rai, A. (2025). Stress: Novel Blood Test Enables Early Pancreatic Cancer Detection. https://www.medscape.com/viewarticle/novel-blood-test-enables-early-pancreatic-cancer-detection-2025a10004w0
